Clinical Trial Results:
            A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells
    
|     Summary | |
|     EudraCT number | 2007-002155-17 | 
|     Trial protocol | GB IT | 
|     Global completion date | 
                                    27 Nov 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    18 Sep 2016
                             | 
|     First version publication date | 
                                    18 Sep 2016
                             | 
|     Other versions | |
|     Summary report(s) | 105594-Clinical-Study-Result-Summary | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
